Objective: To assess therapeutic and preventive effects of comprehensive medical rehabilitation program with individual risk stratification for patients after uterine cancer treatment and impact on their quality of life. Material and Methods: The study was conducted from June 2015 to February 2018 and included 70 patients with early stages of the uterine cancer. Half of the participants underwent the complex of medical rehabilitation and the other formed the control group. At the beginning and in the end of the study following indicators were measured: levels of lower limb lymphedema, cognitive impairment, anxiety, and depression, frequency of thrombotic events, and the quality of life. Individual assessment of the lymphedema and thrombotic event risks was performed. Results: Only in the control group patients developed the lower limb lymphedema (10 cases). Levels of cognitive impairment, anxiety, and depression were significantly lower in the experimental group (anxiety level was even lower than the basic one). Relative risk of thrombotic events was 4.00. Patients from rehabilitation group had significantly higher quality of life according to the EORTC QLQ-C30 questionnaire. Conclusion: Comprehensive medical rehabilitation program with individual risk stratification can significantly improve patient quality of life after uterine cancer treatment. Long-term results can be achieved and maintained in most cases. QOL after rehabilitation interventions can be compared to the one before cancer. In most cases it is possible to achieve and maintain, comparable to the preoperative levels.
rehabilitation, uterine cancer, cognitive impairment, psychotherapy, quality of life
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D.M, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015. March 1;136(5):359-86.
2. Siegel R.L, Miller K.D, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
3. Davydov M.I., Aksel' E.M. Statistika zlokachestvennyh novoobrazovaniy v Rossii i stranah SNG v 2012 g. // M.: Izdatel'skaya gruppa RONC; 2014. 226s.
4. Ballester M, Bendifallah S, Daraï E. Nouvelles recommandations EMSO, ESGO, ESTRO sur la prise en charge des cancers de l'endomètre. Bull Cancer. 2017;104(12):1032-8.
5. Marino J.L, Saunders C.M, Emery L.I, Green H, Doherty D.A, Hickey M. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause. 2014;21(3):267-74.
6. Filonenko E.V., Demidova L.V., Boyko A.V., Urlova A.N., Ivanova-Radkevich V.I. Reabilitaciya onkoginekologicheskih bol'nyh na etapah kombinirovannogo lecheniya. Vestnik vosstanovitel'noy mediciny 2016; 5(75):1-5.
7. Biglia N, Zanfagnin V, Daniele A, Robba E, Bounous V.E. Lower Body Lymphedema in Patients with Gynecologic Cancer. Anticancer Res. 2017;37(8):4005-15.
8. Brown J.C, John G.M, Segal S, Chu C.S, Schmitz K.H. Physical activity and lower limb lymphedema among uterine cancer survivors. Med Sci Sports Exerc. 2013;45(11):2091-7.
9. Janelsins M.C, Kohli S, Mohile S.G, Usuki K, Ahles T.A, Morrow G.R. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011;38(3):431-8.
10. Zeng Y, Cheng A.S.K, Song T, Sheng X, Zhang Y, Liu X, Chan C.C.H. Subjective cognitive impairment and brain structural networks in Chinese gynaecological cancer survivors compared with age-matched controls: a cross-sectional study. BMC Cancer. 2017;17(1):796.
11. Machida H, Hom M.S, Maeda M, Yeo J.J, Ghattas C.S, Grubbs B.H, Matsuo K. Signs and Symptoms of Venous Thromboembolism and Survival Outcome of Endometrial Cancer. Int J Gynecol Cancer. 2016;26(5):924-32.
12. Sekse R.J, Hufthammer K.O, Vika M.E. Fatigue and quality of life in women treated for various types of gynaecological cancers: a cross-sectional study. J Clin Nurs. 2015;24(3-4):546-55.
13. Guntupalli S.R, Sheeder J, Ioffe Y, Tergas A, Wright J.D, Davidson S.A, Behbakht K, Flink D.M. Sexual and marital dysfunction in women with gynecologic cancer. Int J Gynecol Cancer. 2017;27(3):603-7.
14. Khorana A.A, Francis C.W, Culakova E, Lyman G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-9.
15. Kuroda K, Yamamoto Y, Yanagisawa M, Kawata A, Akiba N, Suzuki K, Naritaka K. Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study. BMC Womens Health. 2017;17(1):50.
16. Al-kindi S.G, Oliveira G.H. Incidence and trends of cardiovascular mortality after common cancers in young adults: Analysis of surveillance, epidemiology and end-results program. World J Cardiol. 2016;8(6):368-74.
17. Brown J.C, John G.M., Segal S, Chu C.S, Schmitz K.H. Physical activity and lower limb lymphedema among uterine cancer survivors. Med Sci Sports Exerc. 2013;45(11):2091-7.
18. Horowitz M.A, Zunszain P.A. Neuroimmune and neuroendocrine abnormalities in depression: two sides of the same coin. Ann N Y Acad Sci. 2015;1351:68-79.
19. Fabre B, Grosman H, Gonzalez D, Machulsky N.F, Repetto E.M, Mesch V, Lopez M.A, Mazza O, Berg G. Prostate Cancer, High Cortisol Levels and Complex Hormonal Interaction. Asian Pac J Cancer Prev. 2016;17(7):3167-71.
20. Wolkow A, Aisbett B, Reynolds J, Ferguson S.A, Main L.C. Relationships between inflammatory cytokine and cortisol responses in firefighters exposed to simulated wildfire suppression work and sleep restriction. Physiol Rep. 2015;3(11)
21. Khorana A.A, Carrier M, Garcia D.A, Lee A.Y. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):81-91.
22. Qureshi W, Ali Z, Amjad W, Alirhayim Z, Farooq H, Qadir S, Khalid F, Al-Mallah M.H. Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. Front Cardiovasc Med. 2016;3:24.
23. Gandhi A.V, Mosser E, Oikonomou G, Prober D.A. Melatonin is required for the circadian regulation of sleep. Neuron. 2015;85(6):1193-1199.
24. Li Y, Li S, Zhou Y, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24):39896-921.
25. Janelsins M.C, Kesler S.R, Ahles T.A, Morrow G.R. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102-13.
26. Smith H.R. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Lett. 2015;9(4):1509-14.
27. Hermelink K, Voigt V, Kaste J, Neufeld F, Wuerstlein R, Bühner M, Münzel K, Rjosk-Dendorfer D, Grandl S, Braun M, von Koch F.E, Härtl K, Hasmüller S, Bauerfeind I, Debus G, Herschbach P, Harbeck N. Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. J Natl Cancer Inst. 2015;107(7):99-111.